Stockpolly
Search
PMVP · NASDAQ · Biotechnology

PMV Pharmaceuticals

Develops a precision-oncology therapy for cancers with TP53 Y220C mutations.

$0.9846
Pre-market−0.23 (−18.63%)
At close$1.21(−0.82%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
201918202225222323191919
Research & development141313141714171818161515
6656511444344
General & administrative6056511444344
Other expenses000000000000
Operating income−20−19−18−20−22−25−22−23−23−19−19−19
333332221111
Interest income333332221111
Other non-operating income0−3−3−3−3−2−2−2−1−1−10
Income before tax−17−16−15−17−19−23−20−21−21−18−18−18
Income tax expense000−1600−200000
Net income from continuing operations−17−16−15−1−19−23−17−21−21−18−18−18
Net income−17−16−15−1−19−23−17−21−21−18−18−18
EPS, basic−$0.34−$0.31−$0.30−$0.02−$0.37−$0.45−$0.34−$0.41−$0.40−$0.34−$0.34−$0.34
EPS, diluted−$0.34−$0.31−$0.30−$0.02−$0.37−$0.45−$0.34−$0.41−$0.40−$0.34−$0.34−$0.34
Weighted average shares, basic495151515252525253535353
Weighted average shares, diluted495151515252525253535353
EBITDA−19−15−15−17−19−23−20−21−21−18−18−19
Depreciation & amortization000000000000
EBIT−20−16−15−17−19−23−20−21−21−18−18−19